Chimeric antigen receptors (CAR) are engineered fusion proteins designed to target T cells
to antigens expressed on cancer cells. CAR T cells are now an established treatment for …

Adoptive cell therapy with chimeric antigen receptor (CAR) immunotherapy has made
tremendous progress with five CAR T therapies approved by the US Food and Drug …

Chimeric antigen receptor (CAR) T cells have demonstrated promising efficacy, particularly
in hematologic malignancies. One challenge regarding CAR T cells in solid tumors is the …

Chimeric antigen receptor (CAR) T cells have emerged as a potent therapeutic approach for
patients with certain haematological cancers, with multiple CAR T cell products currently …

Immunotherapies such as immune checkpoint blockade (ICB) and adoptive cell therapy
(ACT) have revolutionized cancer treatment, especially in patients whose disease was …

This Review discusses the major advances and changes made over the past 3 years to our
understanding of chimeric antigen receptor (CAR) T cell efficacy and safety. Recently, the …

Background Several commercial and academic autologous chimeric antigen receptor T-cell
(CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B …

Background Lisocabtagene maraleucel (liso-cel) is an autologous, CD19-directed, chimeric
antigen receptor (CAR) T-cell product. We aimed to assess the activity and safety of liso-cel …

Chimeric antigen receptors (CARs) are engineered proteins designed to target T cells to
cancer cells. To effectively activate the T cells in which they are expressed, CARs must …

OP-EHEA191011_online 2313..2340 Page 1 Low-density lipoproteins cause atherosclerotic
cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus …